Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: A retrospective case series.

被引：0
|
作者：
Chamberlain, Marc C.
Kim, Bryan T.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e13538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13538
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
    Jakobsen, J. N.
    Urup, T.
    Grunnet, K.
    Toft, A.
    Johansen, M. D.
    Poulsen, S. H.
    Christensen, I. J.
    Muhic, A.
    Poulsen, H. S.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (02) : 439 - 446
  • [32] Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
    Schaub, Christina
    Tichy, Julia
    Schaefer, Niklas
    Franz, Kea
    Mack, Frederic
    Mittelbronn, Michel
    Kebir, Sied
    Thiepold, Anna-Luisa
    Waha, Andreas
    Filmann, Natalie
    Banat, Mohammed
    Fimmers, Rolf
    Steinbach, Joachim P.
    Herrlinger, Ulrich
    Rieger, Johannes
    Glas, Martin
    Baehr, Oliver
    JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (01) : 93 - 100
  • [33] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
    Raval, Sumul N.
    Rule, Amy
    Hwang, Shirley S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
  • [34] Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
    Christina Schaub
    Julia Tichy
    Niklas Schäfer
    Kea Franz
    Frederic Mack
    Michel Mittelbronn
    Sied Kebir
    Anna-Luisa Thiepold
    Andreas Waha
    Natalie Filmann
    Mohammed Banat
    Rolf Fimmers
    Joachim P. Steinbach
    Ulrich Herrlinger
    Johannes Rieger
    Martin Glas
    Oliver Bähr
    Journal of Neuro-Oncology, 2016, 129 : 93 - 100
  • [35] RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
    Ahluwalia, Manmeet
    Peereboom, David
    Schilero, Cathy
    Forst, Deborah
    Wong, Eric
    Wen, Patrick
    Reardon, David
    NEURO-ONCOLOGY, 2018, 20 : 234 - 234
  • [36] RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143
    Reardona, D. A.
    Omuroa, A.
    Brandes, A. A.
    Rieger, J.
    Wick, A.
    Sepulveda, J.
    Phuphanich, S.
    de Souza, P.
    Ahluwalia, M. S.
    Lim, M.
    Vlahovicb, G.
    Sampsonb, J.
    NEURO-ONCOLOGY, 2017, 19 : 21 - 21
  • [37] RADIOMIC FEATURES FROM LESION HABITAT PREDICT RESPONSE TO COMBINATION OF NIVOLUMAB AND BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A FEASIBILITY STUDY
    Verma, Ruchika
    Rauf, Yasmeen
    Yadav, Ipsa
    Statsevych, Volodymyr
    Chen, Jonathan
    Evanoff, Wendi
    Ahluwalia, Manmeet
    Tiwari, Pallavi
    NEURO-ONCOLOGY, 2021, 23 : 141 - 141
  • [38] NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; T-CELL REACTIVITY AGAINST AUTOLOGOUS TUMOR CELLS
    Maarup, Simone
    Skadborg, Signe
    Borch, Annie
    Draghi, Arianna
    Hasselbalch, Benedikte
    Ostrup, Olga
    Scheie, David
    Skjoeth-Rasmussen, Jane
    Law, Ian
    Svane, Inge Marie
    Poulsen, Hans
    Hadrup, Sine
    Lassen, Ulrik
    NEURO-ONCOLOGY, 2021, 23 : 54 - 55
  • [39] Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
    Emil Lou
    Ashley L. Sumrall
    Scott Turner
    Katherine B. Peters
    Annick Desjardins
    James J. Vredenburgh
    Roger E. McLendon
    James E. Herndon
    Frances McSherry
    Julie Norfleet
    Henry S. Friedman
    David A. Reardon
    Journal of Neuro-Oncology, 2012, 109 : 63 - 70
  • [40] Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
    Reardon, D. A.
    Herndon, J. E., II
    Peters, K. B.
    Desjardins, A.
    Coan, A.
    Lou, E.
    Sumrall, A. L.
    Turner, S.
    Lipp, E. S.
    Sathornsumetee, S.
    Rich, J. N.
    Sampson, J. H.
    Friedman, A. H.
    Boulton, S. T.
    Bigner, D. D.
    Friedman, H. S.
    Vredenburgh, J. J.
    BRITISH JOURNAL OF CANCER, 2012, 107 (09) : 1481 - 1487
12345